The Vetr crowd upgraded their rating for Illumina, Inc. ILMN on Wednesday, from 2 stars (Sell), issued five days ago, to 4 stars (Buy). Crowd sentiment for Illumina is edging cautious, with 62 percent of Vetr user ratings bearish.
The gene sequencing solutions company provided plenty of indications that it's primed for growth in 2017. In the second week of the year, Illumina provided a strong early report on its 2016 Q4 earnings while also launching an improved model of its sequencing platform.
As a result, the company received a Buy upgrade from Bank of America and shares rose by $23.50, over 16 percent, to $165.04. The price has remained near the the $160 mark since then and ended today at $161.07.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $175.77, which is well above the average analyst target price of the $149.89. Less than 2 percent of Vetr users are holding ILMN in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
